Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
- 10-K/A Annual report
- 4.1 Description of Securities of the Registrant
- 10.1 Rapid Therapeutic Science Laboratories, Inc. 2018 Stock Plan
- 10.4 First Amendment to Exclusive License Agreement Dated June 25, 2020 by and Between Texas Mdi, Inc. and EM3 Methodologies, LLC
- 21.1 Subsidiaries of the Registrant
- 31.1 Certification
- 31.2 Certification
RTSL similar filings
Filing view
External links
Exhibit 31.1
CERTIFICATION PURSUANT TO
15 U.S.C. SECTION 7241 AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Donal R. Schmidt, Jr., certify that:
1.I have reviewed this annual report on Form 10-K/A of Rapid Therapeutic Science Laboratories, Inc. (the “registrant”); and
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
Date: August 26, 2020
/s/ Donal R. Schmidt, Jr.
Donal R. Schmidt, Jr.
Chief Executive Officer
(Principal Executive Officer)